24 studies found for:    dendreon
Show Display Options
Rank Status Study
1 Active, not recruiting Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)
Condition: Prostate Cancer
Intervention: Drug: sipuleucel-T
2 Recruiting Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Sipuleucel-T;   Procedure: Lymph Node Biopsy
3 Completed Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Conditions: Prostatic Neoplasm;   Prostate Cancer;   Prostatic Adenocarcinoma
Interventions: Biological: sipuleucel-T;   Drug: leuprolide acetate
4 Recruiting Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Condition: Prostate Cancer
Intervention: Biological: Sipuleucel-T
5 Recruiting A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
Condition: Castration-Resistant Prostate Cancer
6 Active, not recruiting Open Label Study of Sipuleucel-T
Condition: Prostate Cancer
Intervention: Drug: Sipuleucel-T
7 Unknown  Sipuleucel-T Manufacturing Demonstration Study
Conditions: Cancer of Prostate;   Cancer of the Prostate;   Neoplasms, Prostate;   Neoplasms, Prostatic;   Prostate Cancer;   Prostate Neoplasms;   Prostatic Cancer
Intervention: Biological: sipuleucel-T
8 Active, not recruiting A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Condition: Metastatic Prostate Cancer
Interventions: Biological: sipuleucel-T;   Drug: enzalutamide
9 Active, not recruiting DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02;   Other: Standard of Care
10 Active, not recruiting
Has Results
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of Prostate Adenocarcinoma (PA2024) Antigen
Condition: Prostate Cancer
Intervention: Biological: Sipuleucel-T
11 Active, not recruiting A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Conditions: Advanced Prostate Cancer;   Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
12 Active, not recruiting Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Conditions: Prostate Cancer Metastatic;   Hormone Refractory Prostate Cancer
Interventions: Biological: sipuleucel-T;   Drug: abiraterone acetate
13 Completed
Has Results
Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer
Condition: Prostate Cancer
Interventions: Biological: Sipuleucel-T with Booster;   Biological: Sipuleucel-T without Booster
14 Completed
Has Results
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: sipuleucel-T;   Biological: Placebo
15 Completed Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: EC D-3263 HCl
16 Completed
Has Results
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: Sipuleucel-T;   Biological: APC-Placebo
17 Active, not recruiting Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer
Condition: Prostate Cancer
Interventions: Other: Placebo;   Biological: Provenge
18 Completed
Has Results
Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
Condition: Metastatic Androgen Independent Prostate Cancer
Intervention: Biological: APC8015F
19 Completed
Has Results
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
Condition: Hormone-Refractory Prostate Cancer
Interventions: Biological: sipuleucel-T;   Biological: APC-Placebo
20 Recruiting A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: SipT Treatment;   Drug: Ipilimumab

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Indicates status has not been verified in more than two years